CHRNA7 and Alzheimer disease: Compared with the aforementioned agonists, the main advantage of PNU282987 is that is binds to α7 nAChR specifically and activates α7 nAChR at an efficacy of 100%, thus it has been considered a promising candidate for improving the cognitive function of AD patients.